Paper Details

  1. Home
  2. Paper Details

[Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells].

Author: BaoWen, CaiXiao-Hui, ChenBao-An, ChenJing, ChengJian, DingJia-Hua, GaoFeng, ShenHui-Ling, WangJun, WeiHu-Lai, XuWen-Lin, ZhongYue-Jiao

Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The combination of 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) was found to be effective in reversing multidrug resistance in K562/A02 leukemia cells, promoting apoptosis, and downregulating the expression of survivin mRNA and protein. The combination therapy showed a higher apoptotic rate and lower survivin expression compared to treatment with BrTet or DNR alone.
Paper Details　
Original Abstract of the Article :
The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) on chronic leukemia. The apoptosis of K562/A02 cells treated by DNA, BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry; the expre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21362215

データ提供：米国国立医学図書館（NLM）

5-Bromotetrandrine and Daunorubicin: A Powerful Combination Against Chronic Leukemia?

The fight against chronic leukemia is a relentless battle, and researchers are constantly seeking new and effective weapons in their arsenal. This study explores the potential of combining 5-bromotetrandrine (5-BrTet) with daunorubicin (DNR) to combat this disease. Think of a camel facing a pack of wolves – it needs a strategic advantage to overcome the threat.

The research focuses on K562/A02 cells, a model for chronic leukemia, and investigates the combined effects of 5-BrTet and DNR on apoptosis and survivin expression. This is like studying the tactics and weaknesses of an enemy. The findings suggest that this combination could be a potent weapon against drug-resistant leukemia cells.

A Promising New Strategy for Leukemia Treatment

This research provides valuable insights into the potential of combining 5-BrTet and DNR to combat drug-resistant leukemia. This is like discovering a new oasis with a plentiful supply of water – a much-needed resource in the fight against this disease. The findings suggest that this combination therapy could be a valuable addition to the treatment arsenal for chronic leukemia.

Hope for Leukemia Patients

The potential of 5-BrTet and DNR to overcome drug resistance in leukemia is a beacon of hope. It’s like a camel discovering a hidden trail that leads to a lush valley – a promise of a more favorable outcome. This research offers hope for patients battling chronic leukemia and paves the way for further exploration of this promising therapeutic approach.

Dr.Camel's Conclusion

The fight against chronic leukemia is a formidable challenge. This research, like a camel navigating a treacherous sandstorm, demonstrates the power of perseverance and innovation in seeking new solutions. The combination of 5-BrTet and DNR presents a potential breakthrough in overcoming drug resistance, offering hope for patients and a new direction for leukemia research.

Date :
  1. Date Completed 2012-12-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21362215

DOI: Digital Object Identifier

1009-2137(2011)01-0024-04

Related Literature

Article Analysis
・Effects of daunorubicin
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.